[{"data":1,"prerenderedAt":165},["ShallowReactive",2],{"drug-paricalcitol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":43,"contraindications":72,"warnings":82,"renal":90,"monitoring":91,"interactions":92,"review":93,"examples":96,"atc":105,"iran":107,"usApproval":114,"links":120,"populations":131},"paricalcitol",1,{"fa":7,"en":8},"پاری‌کلسیتول","Paricalcitol","systemic-hormones",{"fa":11,"en":12},"آنالوگ ویتامین D فعال","Active vitamin D analogue",[14],{"name":15,"market":16},"Zemplar","US",[18,19,20],"zemplar","زمپلار","پاریکلسیتول",[22,35],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"vial-5","injection","iv","5 mcg\u002FmL vial",{"amount":28,"unit":29,"perVolumeMl":5},5,"mcg",[16],[32],{"source":33,"section":34},"fda-zemplar-iv","3",{"id":36,"form":24,"route":25,"label":37,"concentration":38,"markets":40,"refs":41},"vial-2","2 mcg\u002FmL vial",{"amount":39,"unit":29,"perVolumeMl":5},2,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":29,"dose":55,"refs":59,"durationDays":62,"notes":63},"hd","secondary-hyperparathyroidism-ckd",{"fa":48,"en":49},"هیپرپاراتیروئیدی ثانویه در CKD مرحله ۵ (دیالیز) — بولوس وریدی ۰٫۰۴ تا ۰٫۱ mcg\u002Fkg حداکثر یک روز در میان حین دیالیز","Secondary hyperparathyroidism in CKD stage 5 (dialysis) — IV bolus 0.04–0.1 mcg\u002Fkg no more often than every other day during dialysis",{"minAge":51},{"value":52,"unit":53},18,"year","weightBased",{"perKgPerDose":56,"perKgPerDoseMax":57,"intervalHours":58},0.04,0.1,24,[60],{"source":33,"section":61},"2.2",{"min":5,"max":5},[64],{"text":65,"refs":68},{"fa":66,"en":67},"پیش از شروع کلسیم بالاتر از حد طبیعی نباشد. کلسیم دو بار در هفته و PTH هر ۲ تا ۴ هفته؛ تیتراسیون با جدول ۱. حداکثر ۰٫۲۴ mcg\u002Fkg.","Calcium must not be above normal before starting. Calcium twice weekly and PTH every 2–4 weeks; titrate per Table 1. Max 0.24 mcg\u002Fkg.",[69,71],{"source":33,"section":70},"2.1",{"source":33,"section":61},[73],{"id":74,"severity":75,"text":76,"refs":79},"ci","block",{"fa":77,"en":78},"هیپرکلسمی؛ مسمومیت با ویتامین D؛ حساسیت به پاری‌کلسیتول.","Hypercalcaemia; vitamin D toxicity; hypersensitivity to paricalcitol.",[80],{"source":33,"section":81},"4",[83],{"text":84,"refs":87},{"fa":85,"en":86},"هیپرکلسمی؛ تشدید مسمومیت دیژیتال با هیپرکلسمی؛ بیماری استخوان آدینامیک با سرکوب بیش از حد PTH.","Hypercalcaemia; digitalis toxicity potentiated by hypercalcaemia; adynamic bone disease with PTH over-suppression.",[88],{"source":33,"section":89},"5",[],[],[],{"status":94,"reviewer":95,"date":95},"unverified",null,[97],{"regimen":45,"formulation":23,"input":98,"expect":101},{"ageYears":99,"weightKg":100},55,70,{"perDose":102,"mlPerDose":103,"upperPerDose":104},2.8,0.56,7,[106],"H05BX02",{"status":108,"refs":109},"not-found",[110],{"source":111,"section":112,"url":113},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Paricalcitol",{"kind":115,"refs":116,"id":119},"NDA",[117],{"source":33,"section":118},"SPL approval \u002F marketing category","NDA020819",[121,124,128],{"kind":122,"url":123,"label":119},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=020819",{"kind":125,"url":126,"label":127},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=7259652f-81bc-4ad1-bba5-d01f9fac1b80","FDA Zemplar injection",{"kind":129,"url":130,"label":106},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=H05BX02",{"pregnancy":132,"lactation":141,"pediatric":149,"geriatric":157},{"level":133,"text":134,"quote":137,"refs":138},"caution",{"fa":135,"en":136},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited data with ZEMPLAR in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage.",[139],{"source":33,"section":140},"8.1",{"level":133,"text":142,"quote":145,"refs":146},{"fa":143,"en":144},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information available on the presence of paricalcitol in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production.",[147],{"source":33,"section":148},"8.2",{"level":133,"text":150,"quote":153,"refs":154},{"fa":151,"en":152},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and efficacy of ZEMPLAR for the prevention and treatment of secondary hyperparathyroidism associated with CKD have been established in pediatric patients 5 years of age and older with CKD on dialysis.",[155],{"source":33,"section":156},"8.4",{"level":133,"text":158,"quote":161,"refs":162},{"fa":159,"en":160},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic or cardiac function, and of concomitant disease or other drug therapy.",[163],{"source":33,"section":164},"8.5",1792191559836]